Insight Molecular Diagnostics Inc.(IMDX)Stock Analysis

IMDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Insight Molecular Diagnostics Inc. (IMDX), a Healthcare sector company. IMDX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Insight Molecular Diagnostics Inc. reports quarterly revenue of $32.0K, net income of $-4.3M, free cash flow of $-8.3M. Top institutional holders of IMDX by reported 13-F value include BROADWOOD CAPITAL, AWM Investment Company,, PURA VIDA INVESTMENTS,, based on the most recent SEC filings. IMDX trades on the Nasdaq exchange and files with the SEC under CIK 1642380. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Insight Molecular Diagnostics Inc. directly from SEC EDGAR.